Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Sail Biomedicines Partners with Johnson & Johnson to Advance In Vivo CAR-T Therapies.

Jul 30, 2026•11 days ago

Contract Type

partnership

SomervilleBiotechnologyHealth CareArtificial Intelligence

Description

Sail Biomedicines has announced a strategic collaboration with Johnson & Johnson to develop innovative In Vivo CAR-T therapies through the combination of Sail's eRNA™ technology and Johnson & Johnson's development capabilities. The agreement includes initial payments totaling $785 million, including a significant equity investment.

Company Information

Company

Sail Biomedicines

Location

Somerville, Pennsylvania, United States

About

Sail Biomedicines, a Flagship Pioneering company, is generating tomorrow’s medicines today through the language of life. Sail’s platform combines first-in-category translatable circular RNA technology (Endless RNA™ or eRNA), and proprietary programmable nanoparticles, utilizing natural components, to comprehensively program medicines for the first time. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability. For more, visit www.sail.bio and follow us on X (formerly Twitter) @SailBiomeds and on LinkedIn.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Sail Biomedicines's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.